SPOTLIGHT: Cardiome, Astellas get panel date

The FDA as extended its review of a new therapy for abnormal heart rhythm and asked Cardiome and Astellas to sit in on a panel review of the drug. The panel review will be held on December 11 and 12 with a decision on the therapy by January 19, 2008. Astellas holds the U.S. marketing rights to the therapy. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.